YOUR VOICE. YOUR EXPERIENCE. YOUR TREATMENT. WHY WE ASKED.
Adding measures of patients’ symptoms, signs, and functions into brain tumor clinical trials will ultimately improve patient care. First, the field – including doctors, researchers, drug makers, and the FDA – need to know what symptoms, signs, and functions are important to patients, though. To get this critical insight to stakeholders in the drug development and approval process, the National Brain Tumor Society distributed a patient and caregiver survey, because the most important voice in this effort is yours – the voice of patients, caregivers and families. These researchers, companies, and regulators need to know what patients want in terms of treatment options. Clearly, living longer and finding a cure is our number one priority. But, there may be treatments that reduce symptoms or improve quality of life, and those treatments need to be evaluated through the clinical trial process.
We thank everyone who took our Survey to help inform these stakeholders in brain tumor drug development.
Learn more about the Clinical Trial Endpoints Initiative here.
We will publish more results from this Survey during the rest of 2015.